Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06218550
Other study ID # IRB00394164
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date July 1, 2024
Est. completion date December 2025

Study information

Verified date May 2024
Source Johns Hopkins University
Contact Ryan Vandrey, PhD
Phone 410-550-4036
Email rvandrey@jhmi.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Delta-8-THC is an isomer of delta-9-THC that has become widely available due to the legalization of hemp and its derivatives. Very little controlled research has been conducted with delta-8-THC and some research suggests it produces similar effects to delta-9-THC, albeit at lower potency. The present study will evaluate the dose effects of delta-8-THC, compared with delta-9-THC, on simulated driving performance, field sobriety tests, cognitive performance, and biomarkers of exposure to cannabinoids. The results will inform policy and education related to impairment due to acute delta-8-THC exposure via vaporization and oral ingestion.


Description:

The present study will characterize the acute effects of oral and inhaled ∆8-THC, compared with a positive control dose of ∆9-THC and placebo, on subjective drug effects, cardiovascular effects, cognitive performance, simulated driving performance, field sobriety tests, and drug testing outcomes in oral fluid, blood, hair, and urine. Healthy adults with a history of cannabis use will be recruited to participate in a placebo-controlled, within-subject crossover study at the Johns Hopkins Behavioral Pharmacology Research Unit (BPRU). The result will be a comparative pharmacology and toxicology dataset for ∆8-THC and ∆9-THC via both oral ingestion and inhalation, two routes of administration that are predominant in retail products currently being sold across the U.S. This study will provide urgently needed data on the behavioral pharmacology and toxicology of ∆8-THC, a novel cannabinoid that is now widely available, but for which there is little public knowledge or public health messaging. This data will directly inform the impact of ∆8-THC use on drug testing programs, and the comparative effects of ∆8-THC to ∆9-THC can be used to inform regulatory decisions related to public safety and the sale of these products.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 45
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: 1. Be between the ages of 18 and 55 2. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests 3. Test negative for recent cannabis use prior to each experimental test session 4. Test negative for drugs of abuse and alcohol prior to each experimental test session 5. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission 6. Have a body mass index (BMI) in the range of 19 to 36 kg/m2 7. Report use of cannabis in the past 3 years (both sub-studies) and prior experience inhaling cannabis (either via smoking or vaporization) for vaporization sub-study participation 8. Have not donated blood in the prior 30 days. 9. Have a current government-issued driver's license Exclusion Criteria: 1. Non-medical use of psychoactive drugs other than nicotine, alcohol, or caffeine in the month prior to study participation. 2. History of or current evidence of health issues judged by the investigator to put the participant at greater risk of experiencing an adverse event due to drug exposure or completion of other study procedures. 3. Current concomitant medication use that may interact with the study drug (?8-THC and ?9-THC). 4. History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples. 5. Participation in other research projects that could impact the present study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Delta-9-THC
Acute self-administration of inhaled or oral ?9-THC by healthy adult research volunteers
Delta-8-THC
Acute self-administration of inhaled or oral ?8-THC by healthy adult research volunteers
Placebo
Consumption of a brownie or inhalation of ambient air through a cannabis vaporizer by health adult research volunteers

Locations

Country Name City State
United States Johns Hopkins Behavioral Pharmacology Research Unit Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University Substance Abuse and Mental Health Services Administration (SAMHSA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Standard Deviation of Lateral Position (SDLP) in cm A measure of lane weaving during simulated driving performance, the standard deviation of lateral position is a standard metric of impairment in driving performance. A score of 0 (perfect score, no deviation) is the minimum score possible and there is no upper threshold score. Higher scores equate to worse performance (more lane weaving). 0-8 hours
Secondary Mean Peak Change From Baseline Drug Effect Rating as Assessed by the Drug Effect Questionnaire (DEQ) Peak rating (0-100) of Drug Effect on the DEQ, a visual analog scale (VAS) self-report questionnaire with 0 being No drug effect and 100 being maximum drug effect 0-8 hours
Secondary Mean Peak Change From Baseline Global Impairment Score as assessed by the DRiving Under the Influence of Drugs (DRUID) App Peak Global Impairment score (0-75) recorded as a result of performance on the DRUID App, a brief cognitive task battery completed on a mobile device (e.g., iPad). Larger scores indicate worse performance on the task. 0-8 hours
See also
  Status Clinical Trial Phase
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04199468 - THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis Phase 1
Completed NCT04587700 - Analgesic Consumption in Chronic Marijuana Users Following Orthopedic Trauma Surgery
Not yet recruiting NCT05899946 - An Integrated Program to Promote Anti-cannabis Messages N/A
Active, not recruiting NCT02735954 - Colorado Marijuana Users Health Cohort
Completed NCT00842985 - Dronabinol Interactions in Humans N/A
Completed NCT04124432 - Behavioral Pharmacology of Cannabis and Nicotine Phase 1
Active, not recruiting NCT04693884 - Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise Early Phase 1
Recruiting NCT03078309 - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients Early Phase 1
Active, not recruiting NCT03560934 - Tetrahydrocannabinol (THC) and Sleep Early Phase 1
Recruiting NCT04704271 - Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II Phase 1
Withdrawn NCT03245658 - The Effect of Cannabis in Pancreatic Cancer Phase 2
Completed NCT04911127 - Therapeutic Response of Cannabidiol in Rheumatoid Arthritis Phase 1
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Recruiting NCT04429568 - THC Crossover Study N/A
Completed NCT05554146 - Pain Inflammation and Cannabis in HIV N/A
Not yet recruiting NCT05320367 - A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users Phase 1/Phase 2
Terminated NCT03251326 - Nabilone in Cannabis Users With PTSD Phase 1/Phase 2
Completed NCT02567344 - Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving N/A
Completed NCT00176085 - Pharmacokinetics of THCCOOH and Its Acyl-glucuronide After Intravenous Administration of THCCOOH Phase 1